Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“Any type of irAE occurs in 80-90% of patients, with higher grade events (as categorized by the Common Terminology Criteria for Adverse Events) occurring in 15-20% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 60% of patients treated with combination of ipilimumab and nivolumab.9”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 2×
“AJCC denotes American Joint Committee on Cancer 2009 classification, 7th edition.(14) 0.”
BackgroundSelf-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citation
Cited by
Items 901–1,000 of 1,000
Moyers, J. T., & Oliva, I. C. G. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_3 · Cited by 13
Is the presence of tumor‐infiltrating lymphocytes predictive of outcomes in patients with melanoma?
Morrison, S. L., Han, G., Elenwa, F., Vetto, J. T., Fowler, G., Leong, S. P. L., Kashani–Sabet, M., Pockaj, B. A., Kosiorek, H., Zager, J. S., et al. (2022) · Cancer · doi:10.1002/cncr.34013 · Cited by 11
Rhodin, K. E., Fimbres, D. C. P., Burner, D., Hollander, S., O'Connor, M. H., & Beasley, G. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021057 · Cited by 11
“Concurrently, two separate studies – Keynote 054 (EORTC 1325), examining adjuvant pembrolizumab (anti-PD1); and COMBI-AD, examining adjuvant dabrafenib/trametinib (BRAF/MEK inhibitors) – returned to the Rotterdam criteria, necessitating at least 1 mm nodal tumor deposit for patients with stage IIIA disease (26, 27).”
BackgroundLiu, X., Xu, C., Guo, T., Zhan, S., Quan, Q., Li, M., Wang, Z., Zhang, X., Guo, L., & Cao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1173524 · Cited by 12
Watson, R. A., Ye, W., Taylor, C. A., Jungkurth, E., Cooper, R. A., Tong, O., James, T., Shine, B. S. F., Hofer, M., Jenkins, D., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008151 · Cited by 11
A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy
Bertolli, E., de Macêdo, M. P., Calsavara, V. F., Pinto, C. A. L., & Neto, J. P. D. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.10.060 · Cited by 12
Song, Y., Azari, F. S., Metzger, D. A., Fraker, D. L., & Karakousis, G. C. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07783-0 · Cited by 11
β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas
Rowe, M., Krishnan, R., Mills, A. M., & Ring, K. L. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001239 · Cited by 11
Chemotherapy in focus: A meta-analysis confronts immunotherapy in the treatment of advanced melanoma
Gonçalves, V. D. M. D. A., Filho, M. F. D. A. C., Zaleski, T., Boas, R. R. V., Ribeiro, E. R., Vaz, R. S., & Cavassin, F. B. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103304 · Cited by 11
Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection
Torphy, R. J., Friedman, C., Ho, F., Leonard, L. D., Thieu, D., Lewis, K. D., Medina, T. M., Robinson, W. A., Gonzalez, R. C., Stewart, C. L., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10775-8 · Cited by 13
Systemic Treatment of Melanoma
Dummer, R., & Goldinger, S. M. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook144 · Cited by 11
Ospina, A. V., Contreras, F., Triana, I. C., Sánchez, G., Ortíz, J. D., Ramos, P. L., Vargas, C., Arango, N., Idrobo, H., Munévar, I., et al. (2023) · JCO Global Oncology · doi:10.1200/go.22.00377 · Cited by 10
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma
Grover, P., Lo, S., Li, I., Kuijpers, A. M. J., Kreidieh, F., Williamson, A. P., Amaral, T., Dimitriou, F., Placzke, J., Olino, K. L., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.021 · Cited by 16
Self-citationMahumud, R. A. (2025) · Cancers · doi:10.3390/cancers17101722 · Cited by 10
“Adjuvant immunotherapy, administered post-surgery or radiotherapy, aims to eliminate residual tumour cells and micro-metastases, thus substantially decreasing recurrence rates and extending disease-free survival [13,14].”
Wong, T., Ch’ng, S., Ferguson, P. M., Martin, L. K., Menzies, A. M., da Silva, I. P., Long, G. V., Scolyer, R. A., van Akkooi, A. C. J., & Lo, S. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104816 · Cited by 11
Self-citationXu, S., Song, Z., Wang, D., Wang, E., & Wang, J. (2025) · BMC Cancer · doi:10.1186/s12885-025-14546-6 · Cited by 10
Cranial nerve outcomes in regionally recurrent head & neck melanoma after sentinel lymph node biopsy
Hanks, J. E., Yalamanchi, P., Kovatch, K. J., Ali, S. A., Smith, J. D., Durham, A. B., Bradford, C. R., Malloy, K. M., & McLean, S. A. (2019) · The Laryngoscope · doi:10.1002/lary.28243 · Cited by 10
Maio, M., Lahn, M., Giacomo, A. M. D., Covre, A., Calabrò, L., Ibrahim, R. A., Fox, B. A., Tank, T. S. T., Abrignani, S., Allavena, P., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02023-4 · Cited by 11
“Ipilimumab alone is an effective treatment in melanoma [48] but when compared to the efficacy and toxicity profile of PD1 inhibitors [49, 50], there is a preference to use pembrolizumab or nivolumab as first line therapy.”
BackgroundSelf-citationMitchell, T. C., Karakousis, G. C., & Schuchter, L. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00066-9 · Cited by 15
Yoshida, T., Yaegashi, H., Toriumi, R., Kadomoto, S., Iwamoto, H., Izumi, K., Kadono, Y., Ikeda, H., & Mizokami, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.912490 · Cited by 12
“Pembrolizumab, an anti-programmed cell death (PD)-1 monoclonal antibody, is known to exhibit antitumor activity in advanced non-small cell lung cancer (8), gastric cancer (9), urothelial carcinoma (10), and malignant melanoma (11).”
BackgroundShi, H., Zeng, T., Liu, Y., Liang, Q., Yang, F., Liang, Y., Fu, Z., Li, W., Li, G., & Yin, Y. (2022) · ACS Materials Letters · doi:10.1021/acsmaterialslett.2c01036 · Cited by 10
Mizoguchi, N., Kano, K., Okuda, T., Koge, H., Shima, S., Tsuchida, K., Takakusagi, Y., Kawashiro, S., Yoshida, M., Kitani, Y., et al. (2024) · Cancers · doi:10.3390/cancers16152625 · Cited by 10
“As adjuvant therapy after CIRT for MMHN, nivolumab is a promising new treatment strategy for suppressing distant metastases and prolonging survival in addition to the favorable LC achieved by CIRT.”
BackgroundKirkwood, J. M., Mohr, P., Höeller, C., Grob, J., Vecchio, M. D., Lord‐Bessen, J., Srinivasan, S., Nassar, A., Campigotto, F., Fairbanks, H., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115371 · Cited by 10
Self-citationDisparity in Outcomes of Melanoma Adjuvant Immunotherapy by Demographic Profile
Ikeguchi, A. P., Machiorlatti, M. G., & Vesely, S. K. (2020) · Melanoma Management · doi:10.2217/mmt-2020-0002 · Cited by 10
Niesert, A., Guertler, A., Schutti, O., Engels, L., Flaig, M. J., French, L. E., Schlaak, M. S., & Reinholz, M. (2021) · Acta Dermato Venereologica · doi:10.2340/00015555-3840 · Cited by 10
Multidisciplinary Care of BRAF -Mutant Stage III Melanoma: A Physicians Perspective Review
Cornelius, L. A., Fields, R. C., & Tarhini, A. A. (2021) · The Oncologist · doi:10.1002/onco.13852 · Cited by 11
“As a result, several factors must be considered in order to individualize adjuvant treatment, including risk of relapse, presence of comorbidities, risk of treatment-related adverse events (TRAEs), and patient preferences.”
BackgroundInfluentialMojtahed, S. A., Boyer, N. R., Rao, S. A., Gajewski, T. F., Tseng, J., & Turaga, K. K. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10288-4 · Cited by 10
Adjuvant PD-L1 blockade in non-small-cell lung cancer
Gainor, J. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02100-0 · Cited by 10
Kujtan, L. A., Kancha, R. K., Gustafson, B., Douglass, L., Ward, C. R., Buzard, B., & Subramanian, J. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2029414 · Cited by 17
Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
Niewolik, J., Mikuteit, M., Cossmann, A., Vahldiek, K., Gutzmer, R., Müller, F., Schröder, D., Heinemann, S., Behrens, G. M. N., Dopfer‐Jablonka, A., et al. (2022) · Oncology · doi:10.1159/000524894 · Cited by 10
Self-citationZhang, S., Chen, S., Wang, Z., Li, J., Yuan, Y., Feng, W., Li, W., Chen, M., & Liu, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1061597 · Cited by 11
“Immunotherapy has proved its value in many cancers (Eggermont et al., 2018; Gandhi et al., 2018; Choueiri et al., 2021; Cortes et al., 2022).”
BackgroundMuhandiramge, J., Warner, E. T., Zalcberg, J. R., Haydon, A. M., Polekhina, G., Londen, G. J. V., Gibbs, P., Bernstein, W. B., Tie, J., Millar, J. L., et al. (2023) · Cancers · doi:10.3390/cancers15041017 · Cited by 10
“Certainly, in the ‘real world’, stage III melanomas may be offered adjuvant targeted therapy [34] or immunotherapy [35], although these treatments were not available during the ASPREE timeframe and are less frequently used in the older population.”
BackgroundSelf-citationSaito, Y., Fujiwara, Y., Miyamoto, Y., Ohnishi, K., Nakashima, Y., Tabata, Y., Baba, H., & Komohara, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.5747 · Cited by 10
Venzel, R., Campos, M. C. P., de Oliveira, L. P., Lins, R. V. D., Siena, Á. D. D., Mesquita, K. T., dos Santos, T. P. M., Nohata, N., Arruda, L. C. M., Sales‐Campos, H., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103988 · Cited by 11
Management of cutaneous melanoma in Australia: a narrative review
Bhave, P., Wong, J., McInerney-Leo, A. M., Cust, A. E., Lawn, C., Janda, M., & Mar, V. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51910 · Cited by 10
Ziętek, M., Teterycz, P., Wierzbicki, J., Jankowski, M., Las‐Jankowska, M., Zegarski, W., Piekarski, J. H., Nejc, D., Drucis, K., Cybulska-Stopa, B., et al. (2023) · Cancers · doi:10.3390/cancers15102667 · Cited by 10
“The RFS curves for patients treated with targeted therapy and anti-PD-1 agents overlap after approximately 2 years, so clear criteria are lacking for choosing one of these therapies in the adjuvant setting [14,15,17,27].”
BackgroundSelf-citationTiming of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?
Rhodin, K. E., Jung, S., Elleson, K. M., DePalo, D. K., Straker, R. J., McKinley, S. K., Beekman, K. E., Parker, L. M., Chen, S. C., Iyer, M. K., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13935-0 · Cited by 12
Russo, D., Dalle, S., Dereure, O., Mortier, L., Dalac, S., Dutriaux, C., Leccia, M. ‐., Legoupil, D., Montaudié, H., Maubec, E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1250026 · Cited by 11
“The advent of targeted therapies and immunotherapy in the adjuvant and neo-adjuvant settings brings new issues such as which treatment should be favored in the context of BRAF mutated melanomas (3, 13, 14).”
BackgroundSelf-citationEducational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma
Su, D. G., Kluger, H. M., & Olino, K. L. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14587-w · Cited by 11
Cellular therapy against public neoantigens
Armistead, P. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126116 · Cited by 12
Mangana, J., Dimitriou, F., Braun, R. P., Ludwig, S., Dummer, R., & Barysch, M. J. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000593 · Cited by 10
Urbani, F., Ferraresi, V., Capone, I., Macchia, I., Palermo, B., Nuzzo, C. M. A., Torsello, A., Pezzotti, P., Giannarelli, D., Pozzi, A. F., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00202 · Cited by 13
“Starting in 2015, three CPIs have been approved for the adjuvant treatment of melanoma by FDA and EMA, that is, ipilimumab (38, 39), nivolumab (40), and pembrolizumab (41).”
BackgroundTumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma
Levine, L. S., Mahuron, K. M., Tsai, K. K., Wu, C., Mattis, D. M., Pauli, M. L., Oglesby, A., Lee, J., Spitzer, M. H., Krummel, M. F., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08648-7 · Cited by 13
Keukeleire, S. D., Schwarze, J. K., Awada, G., Everaert, H., Vanbinst, A., Cras, L., Neyns, B., & Aspeslagh, S. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000680 · Cited by 10
Identification of prognostic mRNAs in metastatic cutaneous melanoma
Lee, S., Suh, H. B., Choi, S. J., Kang, J., Kang, J. W., Kwon, E. J., Kim, H. J., Kim, Y. H., & Shin, K. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000697 · Cited by 10
Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art
Saux, O. L., Lounici, Y., Wajda, P., Ghamry-Barrin, S., Caux, C., Dubois, B., & Ray-Coquard, I. L. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103172 · Cited by 10
Tumors of the Nail Apparatus and Adjacent Tissues
Pasch, M. C., Haneke, E., Baran, R., Thomas, L., & Richert, B. (2018) · Wiley eBooks · doi:10.1002/9781119323396.ch21 · Cited by 10
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology
Frega, S., Maso, A. D., Pasello, G., Cuppari, L., Bonanno, L., Conte, P., & Evangelista, L. (2020) · Cancers · doi:10.3390/cancers12051303 · Cited by 10
“Ipilimumab Malignant melanoma [6] Nivolumab Malignant melanoma [7] Pembrolizumab Malignant melanoma [8]”
BackgroundMcCabe, M. J., Pinese, M., Chan, C., Sheriff, N., Thompson, T. J., Grady, J. P., Wong, M., Gauthier, M.-E. A., Puttick, C., Gayevskiy, V., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003764 · Cited by 10
“…this patient to receive a combination treatment in the event of relapse that would recruit T lymphocytes into the tumor microenvironment (e.g., anti-CTLA4 [ipilimumab]), but also inhibit PD-L1 if progression had occurred (e.g., anti-PD-1 [pembrolizumab]) (Pai et al. 2017; Eggermont et al. 2018).”
BackgroundBai, X., Attrill, G. H., Gide, T. N., Ferguson, P. M., Nahar, K. J., Shang, P., Vergara, I. A., Palendira, U., da Silva, I. P., Carlino, M. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47301-9 · Cited by 9
Self-citationImmune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling
Wu, L., Park, S.-H., Jakobsson, H., Shackleton, M. J., & Möller, A. (2024) · Cancers · doi:10.3390/cancers16111950 · Cited by 10
“The use of immunotherapy has also extended to the treatment of patients with lo-coregionally advanced disease who undergo curative-intent surgery, nowadays offered in both adjuvant [48,49] and neoadjuvant [50] treatment contexts.”
BackgroundWang, Z., Zou, X., Wang, H., Hao, Z., Li, G., & Wang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454720 · Cited by 15
Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting
Liang, K.-L., & Azad, N. S. (2025) · Cancers · doi:10.3390/cancers17071246 · Cited by 10
“After showing initial success in metastatic patients, ICI therapy has demonstrated a substantial survival benefit and is now the standard of care in the adjuvant setting in multiple tumor types, including lung cancer, melanoma, urothelial cancer, and others [9–13].”
Wang, Z., Li, L., Huang, P., Tu, H., Zhang, X., Lei, Y., Liang, F., Huang, C., Qiu, S., Ye, Q., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00268-7 · Cited by 10
Wang, X., Haaland, B. A., Hu‐Lieskovan, S., Colman, H., & Holmen, S. L. (2021) · Cancer Reports · doi:10.1002/cnr2.1419 · Cited by 14
Ge, Y., Zhang, H., Weygant, N., & Yao, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640099 · Cited by 10
Yamazaki, N., Shimizu, A., Ozaki, M., Hamada, M., Takeuchi, N., Ito, Y., & Maekawa, S. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16518 · Cited by 9
Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature
Berciano‐Guerrero, M., Guardamagna, M., Pérez-Ruiz, E., Jurado, J. M., Barragán, I., & Rueda‐Domínguez, A. (2022) · Life · doi:10.3390/life12091302 · Cited by 11
Multiple primary malignant neoplasm: Case report and comprehensive literature review
Ma, X., Tian, K., & Sun, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1090634 · Cited by 9
Long-term outcomes of stage IIB–IV melanoma patients: nationwide data from Norway
Winge-Main, A., Robsahm, T. E., Nyakas, M., Festervoll, G., Torkilseng, E. B., Thybo, S., Pati, S., & Carroll, R. (2023) · Future Oncology · doi:10.2217/fon-2022-0969 · Cited by 9
An estrogen response-related signature predicts response to immunotherapy in melanoma
Lin, M., Du, T., Tang, X., Liao, Y., Cao, L., Zhang, Y., Zheng, W., & Zhou, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109300 · Cited by 9
“Immune checkpoint inhibitors such as anti-programmed cell death 1 (anti-PD-1) significantly improve relapse-free survival in patients with resected stage III/IV melanomas (3, 4).”
BackgroundMooradian, M. J., & Sullivan, R. J. (2023) · Cancer · doi:10.1002/cncr.34806 · Cited by 9
Mishima, S., Naito, Y., Akagi, K., Hayashi, N., Hirasawa, A., Hishiki, T., Igarashi, A., Ikeda, M., Kadowaki, S., Kajiyama, H., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02397-9 · Cited by 9
“level: Not recommended [SR: 0, R: 0, ECO: 8, NR: 12] For malignant melanoma, an anti-PD-1 antibody drug has demonstrated efficacy as postoperative adjuvant therapy and has been approved (KEYNOTE-054 study [73] and ONO-4538-21 study [74]).”
BackgroundSheng, F., Yan, Y., & Zeng, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1284240 · Cited by 11
Yang, H., Ding, Z., An, Z., Zhao, Y. X., & Lu, H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2343023 · Cited by 9
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma
Esmaeli, B., Ogden, T., Nichols, M., Lu, T. J., Debnam, J. M., Dimitriou, F., McQuade, J. L., & Oliva, I. C. G. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000001016 · Cited by 10
Erdmann, M., SIGLER, D., Uslu, U., Göhl, J., Grützmann, R., Schuler, G., & Schellerer, V. S. (2018) · Anticancer Research · doi:10.21873/anticanres.13024 · Cited by 9
Jiang, Q., Feng, M., Li, Y., Lang, J., Wei, H., & Yu, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574511 · Cited by 9
Wang, Y., Li, Z., Zhang, Z., & Chen, X. (2021) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12154 · Cited by 9
“The effect of pembrolizumab was not related to the expression of PD-L1 [10].”
BackgroundUnusual severe gastritis and gastric ulcers caused by pembrolizumab
Liu, W.-T., Li, Y., & Hsieh, T. (2021) · Journal of Postgraduate Medicine · doi:10.4103/jpgm.jpgm_1132_20 · Cited by 9
“[3] High-risk factors for development of irAEs include underlying autoimmune diseases and the combination of two immune checkpoint inhibitors.”
Nguyen, A. T., Luu, M., Nguyen, V. P., Hamid, O., Faries, M. B., Gharavi, N. M., Lu, D. J., Clair, J. M., Ho, A. S., & Zumsteg, Z. S. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2021.4298 · Cited by 9
Ogata, D., Tanese, K., Nakamura, Y., Otsuka, M., Namikawa, K., Funakoshi, T., Yoshikawa, S., Tsutsui, K., Nakama, K., Jinnai, S., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02029-0 · Cited by 9
Ramtohul, T., Cohen, A., Rodrigues, M. J., Piperno-Neumann, S., Cabel, L., Cassoux, N., Rouïc, L. L.-L., Malaise, D., Gardrat, S., Pierron, G., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01793-8 · Cited by 9
Management of Head and Neck Mucosal Melanoma
Nenclares, P., & Harrington, K. J. (2022) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2021.11.008 · Cited by 9
Walker, R. J. B., Hong, N. J. L., Moncrieff, M. D., van Akkooi, A. C. J., Jost, E., Nessim, C., van Houdt, W. J., Stahlie, E. H. A., Seo, C., Quan, M. L., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11936-z · Cited by 9
Kurzhals, J. K., Klee, G., Hagelstein, V., Zillikens, D., Terheyden, P. A. M., & Langan, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810723 · Cited by 9
“The CheckMate 238 and Keynote-054 clinical trials both demonstrated significantly longer recurrence-free survival for patients treated with immunotherapy in this setting [14,15] The Keynote-054 reported a distant free survival of 65.”
BackgroundHussain, Z., Heaton, M. J., Snelling, A. P., Nobes, J. P., Gray, G., Garioch, J., & Moncrieff, M. D. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12804-6 · Cited by 9
Mo, Z., Liu, J., Zhang, J., Deng, Y., Xu, M., & Jiang, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110973 · Cited by 10
Wang, R., Chen, Y., Xie, Y., Ma, X., & Liu, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111989 · Cited by 10
Adjuvant and Neoadjuvant Treatment of Skin Cancer
Sacco, A. G., & Daniels, G. A. (2018) · Facial Plastic Surgery Clinics of North America · doi:10.1016/j.fsc.2018.08.014 · Cited by 10
Bloemendal, M., Rietveld, M. J. A., van Willigen, W. W., Gerritsen, W. R., Figdor, C. G., Bonenkamp, H. J., Westdorp, H., Boudewijns, S., Koornstra, R. H. T., Adang, E., et al. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1987-0 · Cited by 9
Self-citationManagement of local or regional non‐nodal disease
Racz, J. M., Block, M. S., Baum, C. L., & Jakub, J. W. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25330 · Cited by 9
Ipenburg, N. A., Nieweg, O. E., Ahmed, T., van Doorn, R., Scolyer, R. A., Long, G. V., Thompson, J. F., & Lo, S. (2019) · British journal of surgery · doi:10.1002/bjs.11262 · Cited by 9
Self-citationThe Era of Checkpoint Inhibition: Lessons Learned from Melanoma
Paschen, A., & Schadendorf, D. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_6 · Cited by 9
Self-citationUpregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas
Verver, D., Poirier-Colame, V., Tomasic, G., Cherif-Rebai, K., Grünhagen, D. J., Verhoef, C. K., Suciu, S., Robert, C., Zitvogel, L., & Eggermont, A. M. M. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1660121 · Cited by 9
Self-citationThe Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre
Tie, E. N., Na, L. H., Hicks, R. J., Spillane, J. B., Speakman, D., Henderson, M. A., & Gyorki, D. E. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07965-w · Cited by 9
Rapport, F., Smith, A. L., Cust, A. E., Mann, G. J., Watts, C. G., Gyorki, D. E., Henderson, M. A., Hong, A., Kelly, J. W., Long, G. V., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032636 · Cited by 9
Self-citationCost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma
Hu, Y., Briggs, A. H., Marchetti, M. A., Ariyan, C. E., Coit, D. G., & Bartlett, E. K. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.08.750 · Cited by 9
“These projections were derived from survival outcomes published in randomized trials designed in the AJCC 7th edition era (4, 5, 7, 12, 13), and are lower than the 88% described by AJCC 8th edition (3).”
BackgroundMethodResultInfluentialSentinel node biopsy for primary cutaneous melanoma
Faries, M. B., Testori, A., & Gershenwald, J. E. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.007 · Cited by 9
Pure and Mixed Desmoplastic Melanomas: A Retrospective Clinicopathologic Comparison of 33 Cases
Chu, S., Schrom, K. P., Tripathi, R., Conic, R. R. Z., Ezaldein, H. H., Scott, J. F., & Honda, K. S. (2021) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001909 · Cited by 9
Khushalani, N. I., Vassallo, M., Goldberg, J. D., Eroglu, Z., Kim, Y., Cao, B., Ferguson, R., Monson, K. R., Kirchhoff, T., Amato, C. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005684 · Cited by 9
Cancer burden in the United States—a review
Islami, F., Miller, K. D., & Jemal, A. (2018) · Annals of Cancer Epidemiology · doi:10.21037/ace.2018.08.02 · Cited by 10
“For example, adjuvant therapy with pembrolizumab or nivolumab (monoclonal antibodies against programmed death 1) has increased progression-free and overall survival in advanced melanoma (77,78).”
BackgroundIs single versus combination therapy problematic in the treatment of cutaneous melanoma?
Krattinger, R., Ramelyte, E., Dornbierer, J., & Dummer, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1650641 · Cited by 10
A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches
Bossi, P., Airoldi, M., Spiriti, M. A. A., Antonuzzo, A., Bonciarelli, G., Campagna, A., Cassano, A., Murialdo, R., Musio, D., & Silvano, G. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1724955 · Cited by 9
“ipilimumab, pembrolizumab, nivolumab) [44,45] ● Numerous targeted treatments have also been developed [46]”
BackgroundTargeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma
Ma, V. T.-L., Haring, C. T., Warrier, G., & Swiecicki, P. L. (2020) · Facial Plastic Surgery · doi:10.1055/s-0040-1709126 · Cited by 9
Gu, Y., Zhang, H., Liu, Z., Xia, Y., Liang, B., & Liang, L. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13385 · Cited by 11
PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma
Marcaillou, M., Linder, C., Chaltiel, L., Sibaud, V., Pagès, C., Modesto, A., Chira, C., Dalmasso, C., Boulinguez, S., Bédane, C., et al. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000700 · Cited by 9
Estimation of Distant Metastasis–free Survival in Trials of Adjuvant Therapy for Melanoma
Eggermont, A. M. M., Suciu, S., & Kicinski, M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1902228 · Cited by 9
Self-citationElsayed, A., Plüss, L., Nideroest, L., Rotta, G., Thoma, M., Zangger, N. S., Peissert, F., Pfister, S. K., Pellegrino, C. E., Plaza, S. D., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0766 · Cited by 10
Cuiffo, B., Maxwell, M., Yan, D., Guemiri, R., Boone, A., Bellet, D., Rivest, B., Cardia, J. P., Robert, C., & Fricker, S. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1501679 · Cited by 11
Self-citation
Metadata
- Authors
- Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C.
- Affiliations
- Aix-Marseille Université (FR)
- From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical...
- The University of Sydney (AU)
- The University of Queensland (AU)
- Edith Cowan University (AU)
- Washington University in St. Louis (US)
- University of Siena (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Eggermont, Alexander M.M.
- Blank, Christian U.
- Long, Georgina V.
- Atkinson, Victoria
- Dalle, Stéphane
- Haydon, Andrew
- Khattak, Adnan
- Carlino, Matteo S.
- Sandhu, Shahneen
- Larkin, James
- Puig, Susana
- Ascierto, Paolo A.
- Rutkowski, Piotr
- Schadendorf, Dirk
- Koornstra, Rutger
- Hernandez-Aya, Leonel
- Maio, Michele
- Grob, Jean-Jacques
- Gutzmer, Ralf
- Jamal, Rahima
- Lorigan, Paul
- Ibrahim, Nageatte
- Marreaud, Sandrine
- Suciu, Stefan
- Robert, Caroline
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1789-1801
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2797309423
- Cited by
- 1,906
- References
- 31
- Citations by year
- 2026: 131 · 2025: 171 · 2024: 207 · 2023: 204 · 2022: 236 · 2021: 308 · 2020: 307 · 2019: 250 · 2018: 87
- FWCI
- 88.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, adjuvant therapy, stage III melanoma, PD-1 inhibitors, PD-L1 expression, recurrence-free survival, resected melanoma, immune checkpoint inhibitors, adverse events, myositis, non-relapse mortality, overall survival, progression-free survival, high-risk melanoma, tumor recurrence prevention, safety and tolerability
- MeSH terms
- Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.